SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Promising but Not Clinically Significant, Vaccinex’s Huntington’s Drug Misses the Mark
Vaccinex announced topline data from the early manifest treatment arm of its Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease.
September 22, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: September 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
September 21, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
BioCapital
ESMO News: AstraZeneca, Merck, Janssen, Amgen and More
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
September 21, 2020
 · 
4 min read
 · 
Mark Terry
Sitravatinib is showing positive results.
Drug Development
Mirati’s Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
San Diego-based Mirati Therapeutics, a clinical-stage biotechnology company, is currently developing sitravatinib to address unmet medical needs in cancer care.
September 20, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and More
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
September 18, 2020
 · 
4 min read
 · 
Alex Keown
BioForest
Clinical Catch-Up: September 14-18
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
September 18, 2020
 · 
11 min read
 · 
Mark Terry
Drug Development
Regeneron and Sanofi’s Checkpoint Inhibitor Shines in Phase II BCC Study
Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
September 18, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: September 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
September 17, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Jonathan Weiss/Shutterstock
Drug Development
Eli Lilly’s Antibody Therapy Against COVID-19 Reduced Hospitalization Rates
Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19.
September 16, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: September 16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
September 16, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
April 16, 2024
 · 
3 min read
Drug Development
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
April 16, 2024
 · 
5 min read
Drug Development
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
April 16, 2024
 · 
4 min read
Drug Development
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
April 16, 2024
 · 
9 min read
Business
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 16, 2024
 · 
5 min read
Drug Development
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
April 16, 2024
 · 
5 min read
Drug Development
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
April 16, 2024
 · 
7 min read
Drug Development
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024
 · 
4 min read
Drug Development
First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
April 15, 2024
 · 
8 min read
Drug Development
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 15, 2024
 · 
7 min read
Drug Development
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
April 15, 2024
 · 
9 min read
Drug Development
Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
April 15, 2024
 · 
8 min read
Drug Development
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024
 · 
4 min read
Drug Development
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 15, 2024
 · 
3 min read
Drug Development
Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome
April 15, 2024
 · 
2 min read
Drug Development
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
April 15, 2024
 · 
7 min read
Drug Development
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
April 15, 2024
 · 
8 min read
Drug Development
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
April 15, 2024
 · 
12 min read
Drug Development
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
April 15, 2024
 · 
7 min read
Drug Development
T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured
April 12, 2024
 · 
2 min read
Load More